← Back to Clinical Trials
Recruiting NCT06618612

A Study to Evaluate the Efficacy of a Purified Native Type 1 Collagen Extracellular Matrix With Polyhexamethylene Biguanide Antimicrobial (PCMP) and Standard of Care Versus Standard of Care Alone in the Management of Nonhealing Diabetic Foot Ulcers

Trial Parameters

Condition Diabetic Foot Ulcer
Sponsor Organogenesis
Study Type INTERVENTIONAL
Phase N/A
Enrollment 170
Sex ALL
Min Age 18 Years
Max Age N/A
Start Date 2024-08-19
Completion 2026-08-19
Interventions
Standard of CarePuraPly AMPuraPly XT

Brief Summary

This prospective, multi-center, randomized, controlled modified platform Trial compares Purified Native Type 1 Collagen Extracellular Matrix with Polyhexamethylene Biguanide Antimicrobial (PCMP) and Standard of Care versus Standard of Care Alone in subjects with chronic DFUs.

Eligibility Criteria

Inclusion Criteria: 1. At least 18 years of age or older. 2. Diagnosis of type 1 or 2 Diabetes mellitus. 3. At enrollment, target ulcer with a minimum surface area of 1.0 cm2 4. The target ulcer must have been present for a minimum of 4 weeks 5. The target ulcer must be located on the foot with at least 50% of the ulcer below the malleolus. 6. The target ulcer must be Wagner 1 or 2 grade 7. The affected limb must have adequate perfusion confirmed by vascular assessment. 8. If the potential subject has two or more ulcers, they must be separated by at least 2 cm. The largest ulcer satisfying the inclusion and exclusion criteria will be designated as the target ulcer. 9. Target ulcers located on the plantar aspect of the foot must be offloaded for at least 14 days prior to enrollment. 10. The potential subject must consent to using the prescribed offloading method for the duration of the study. 11. The potential subject must agree to attend the weekly study visits required by the protocol

Related Trials